211 related articles for article (PubMed ID: 22410436)
1. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome.
Keshavjee S; Gelmanova IY; Shin SS; Mishustin SP; Andreev YG; Atwood S; Furin JJ; Miller A
Int J Tuberc Lung Dis; 2012 May; 16(5):596-603. PubMed ID: 22410436
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia.
Shin SS; Pasechnikov AD; Gelmanova IY; Peremitin GG; Strelis AK; Mishustin S; Barnashov A; Karpeichik Y; Andreev YG; Golubchikova VT; Tonkel TP; Yanova GV; Nikiforov M; Yedilbayev A; Mukherjee JS; Furin JJ; Barry DJ; Farmer PE; Rich ML; Keshavjee S
Int J Tuberc Lung Dis; 2006 Apr; 10(4):402-8. PubMed ID: 16602404
[TBL] [Abstract][Full Text] [Related]
3. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
[TBL] [Abstract][Full Text] [Related]
4. Predictors and mortality associated with treatment default in pulmonary tuberculosis.
Kliiman K; Altraja A
Int J Tuberc Lung Dis; 2010 Apr; 14(4):454-63. PubMed ID: 20202304
[TBL] [Abstract][Full Text] [Related]
5. Alcohol use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation.
Miller AC; Gelmanova IY; Keshavjee S; Atwood S; Yanova G; Mishustin S; Furin JJ; Shin SS
Int J Tuberc Lung Dis; 2012 Jul; 16(7):891-6. PubMed ID: 22507895
[TBL] [Abstract][Full Text] [Related]
6. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia.
Shin SS; Pasechnikov AD; Gelmanova IY; Peremitin GG; Strelis AK; Mishustin S; Barnashov A; Karpeichik Y; Andreev YG; Golubchikova VT; Tonkel TP; Yanova GV; Yedilbayev A; Rich ML; Mukherjee JS; Furin JJ; Atwood S; Farmer PE; Keshavjee S
Int J Tuberc Lung Dis; 2007 Dec; 11(12):1314-20. PubMed ID: 18034952
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
[TBL] [Abstract][Full Text] [Related]
8. Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment.
Ngouleun W; Biapa Nya PC; Pieme AC; Telefo PB
Int J Mycobacteriol; 2016 Dec; 5(4):482-488. PubMed ID: 27931691
[TBL] [Abstract][Full Text] [Related]
9. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003.
Brust JC; Gandhi NR; Carrara H; Osburn G; Padayatchi N
Int J Tuberc Lung Dis; 2010 Apr; 14(4):413-9. PubMed ID: 20202298
[TBL] [Abstract][Full Text] [Related]
10. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis.
Younossian AB; Rochat T; Ketterer JP; Wacker J; Janssens JP
Eur Respir J; 2005 Sep; 26(3):462-4. PubMed ID: 16135729
[TBL] [Abstract][Full Text] [Related]
11. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.
Bloss E; Kuksa L; Holtz TH; Riekstina V; Skripconoka V; Kammerer S; Leimane V
Int J Tuberc Lung Dis; 2010 Mar; 14(3):275-81. PubMed ID: 20132617
[TBL] [Abstract][Full Text] [Related]
12. Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity.
Warmelink I; ten Hacken NH; van der Werf TS; van Altena R
Br J Nutr; 2011 Feb; 105(3):400-8. PubMed ID: 20875187
[TBL] [Abstract][Full Text] [Related]
13. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
Nathanson E; Gupta R; Huamani P; Leimane V; Pasechnikov AD; Tupasi TE; Vink K; Jaramillo E; Espinal MA
Int J Tuberc Lung Dis; 2004 Nov; 8(11):1382-4. PubMed ID: 15581210
[TBL] [Abstract][Full Text] [Related]
14. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria.
Isa SE; Ebonyi AO; Shehu NY; Idoko P; Anejo-Okopi JA; Simji G; Odesanya RU; Abah IO; Jimoh HO
Int J Mycobacteriol; 2016 Mar; 5(1):21-6. PubMed ID: 26927986
[TBL] [Abstract][Full Text] [Related]
15. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore.
Teleman MD; Chee CB; Earnest A; Wang YT
Int J Tuberc Lung Dis; 2002 Aug; 6(8):699-705. PubMed ID: 12150482
[TBL] [Abstract][Full Text] [Related]
16. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
[TBL] [Abstract][Full Text] [Related]
17. Multidrug-resistant tuberculosis in New South Wales, Australia, 1999-2010: a case series report.
Roberts-Witteveen A; Reinten T; Christensen A; Sintchenko V; Seale P; Lowbridge C
Int J Tuberc Lung Dis; 2015 Jul; 19(7):850-6. PubMed ID: 26056113
[TBL] [Abstract][Full Text] [Related]
18. Treatment of MDR-TB: is hepatotoxicity a problem?
Loddenkemper R; Schaberg T
Int J Tuberc Lung Dis; 2012 May; 16(5):571. PubMed ID: 22507929
[No Abstract] [Full Text] [Related]
19. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
[TBL] [Abstract][Full Text] [Related]
20. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors.
Shakya R; Rao BS; Shrestha B
Ann Pharmacother; 2004 Jun; 38(6):1074-9. PubMed ID: 15122004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
